Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU Novartis Accessed on 4 Jan 2012 from http://www.novartis.com/newsroom/media-releases/en/2011/1498377.shtml. CommentRecommendBookmarkWatch